Johanna S. Salzer

Johanna S. Salzer

Auto-generated profile, based on publicly available information

Johanna S. Salzer

Rickettsial Zoonoses Branch, Division of Vector-borne Disease, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
JTJulie M. Thompson
Julie M. Thompson
ACAnn Carpenter
Ann Carpenter
GKGilbert J. Kersh
Gilbert J. Kersh
TWTyler Wachs
Tyler Wachs
SCScott P. Commins
Scott P. Commins
JSJohanna S. Salzer
Johanna S. Salzer
This report describes the number of suspected Alpha-gal syndrome cases in the United States.

20 July 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
MKM. Shannon Keckler
M. Shannon Keckler
JSJohanna S Salzer
Johanna S Salzer
NPNishi Patel
Nishi Patel
MTMichael Townsend
Michael Townsend
YNYoshinori Nakazawa
Yoshinori Nakazawa
IDInger K Damon
Inger K Damon
The protection provided by smallpox vaccines when used after exposure to Orthopoxviruses is poorly understood. Postexposu re administration of 1st generation smallpox vaccines was effective during eradication. However, historical epidemiological reports and animal studies on postexposure vaccination are difficult to extrapolate to today’s populations, and 2nd and 3rd generation vaccines, developed after eradication, have not been widely tested in postexposure vaccination scenarios. In addition to concerns about preparedness for a potential malevolent reintroduction of variola virus, humans are becoming increasingly exposed to naturally occurring zoonotic orthopoxviruses and, following these exposures, disease severity is worse in individuals who never received smallpox vaccination. This study investigated whether postexposure vaccination of prairie dogs with 2nd and 3rd generation smallpox vaccines was protective against monkeypox disease in four exposure scenarios. We infected animals with monkeypox virus at doses of 104 pfu (2× LD50) or 106 pfu (170× LD50) and vaccinated the animals with IMVAMUNE® or ACAM2000® either 1 or 3 days after challenge. Our results indicated that postexposure vaccination protected the animals to some degree from the 2× LD50, but not the 170× LD5 challenge. In the 2× LD50 challenge, we also observed that administration of vaccine at 1 day was more effective than administration at 3 days postexposure for IMVAMUNE®, but ACAM2000® was similarly effective at either postexposure vaccination time-point. The effects of postexposure vaccination and correlations with survival of total and neutralizing antibody responses, protein targets, take formation, weight loss, rash burden, and viral DNA are also presented.

1 April 2025 in Emerging Infectious Diseases
Verified
Journal Article
Open access
ESEleanor F. Saunders
Eleanor F. Saunders
HSHaris Sohail
Haris Sohail
DMDevin J. Myles
Devin J. Myles
DCDawn Charnetzky
Dawn Charnetzky
BABryan N. Ayres
Bryan N. Ayres
JSJohanna S. Salzer
Johanna S. Salzer
In the United States, alpha-gal syndrome (AGS) is primarily associated with lone star tick (Amblyomma americanum) bites. We describe AGS onset after an Ixodes scapularis tick bite and present AGS surveillance in Maine, 2014-2023. US health and public health professionals should be aware of AGS outside the established lone star tick range.

6 November 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
GAGERARDO ALVAREZ
GERARDO ALVAREZ
RLRuy López-Ridaura
Ruy López-Ridaura
RCRicardo Cortés-Alcalá
Ricardo Cortés-Alcalá
GRGABRIEL GARCÍA RODRÍGUEZ
GABRIEL GARCÍA RODRÍGUEZ
JCJ R Tadeo Calleja-López
J R Tadeo Calleja-López
DWDavid Walker
David Walker
: Rocky Mountain spotted fever (RMSF) is an ongoing public health crisis in Mexico, particularly in states bordering the United States. The national highest incidence and mortality of RMSF occur in this region, resulting in a case-fatality rate that ranges annually between 10% and 50%, primarily affecting vulnerable groups such as children, elderly adults, and persons living in poverty. Multiple biological, environmental, and social determinants can explain its growing presence throughout the country and how it challenges the health system and society. It is necessary to integrate resources and capacities from health authorities, research centers, and society to succeed in dealing with this problem. Through a scientific symposium, a group of academicians, U.S. health officials, and Mexican health authorities met on November 8–10, 2023, in Hermosillo, Mexico, to discuss the current situation of RMSF across the country and the challenges associated with its occurrence. An urgent call for action to improve national capacity against RMSF in the aspects of epidemiological and acarological surveillance, diagnosis, medical care, case and outbreak prevention, health promotion, and research was urged by the experts. The One Health approach is a proven multidisciplinary strategy to integrate policies and interventions to mitigate and prevent the burden of cases, deaths, and suffering caused by RMSF in Mexico.

4 December 2018 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
HAHari Krishna Ananthula
Hari Krishna Ananthula
SPScott Parker
Scott Parker
ETErin Touchette
Erin Touchette
RBR. Mark Buller
R. Mark Buller
GPGopi Patel
Gopi Patel
PDPankaj Desai
Pankaj Desai
Several tyrosine kinase inhibitors (TKIs) developed as anti-cancer drugs, also have anti-viral activity due to their ability to disrupt productive replication and dissemination in infected cells. Consequently, such drugs are attractive candidates for “repurposing” as anti-viral agents. However, clinical evaluation of therapeutics against infectious agents associated with high mortality, but low or infrequent incidence, is often unfeasible. The United States Food and Drug Administration formulated the “Animal Rule” to facilitate use of validated animal models for conducting anti-viral efficacy studies. To enable such efficacy studies of two clinically approved TKIs, nilotinib, and imatinib, we first conducted comprehensive pharmacokinetic (PK) studies in relevant rodent and non-rodent animal models. PK of these agents following intravenous and oral dosing were evaluated in C57BL/6 mice, prairie dogs, guinea pigs and Cynomolgus monkeys. Plasma samples were analyzed using an LC-MS/MS method. Secondarily, we evaluated the utility of allometry-based inter-species scaling derived from previously published data to predict the PK parameters, systemic clearance (CL) and the steady state volume of distribution (Vss) of these two drugs in prairie dogs, an animal model not tested thus far. Marked inter-species variability in PK parameters and resulting oral bioavailability was observed. In general, elimination half-lives of these agents in mice and guinea pigs were much shorter (1–3 h) relative to those in larger species such as prairie dogs and monkeys. The longer nilotinib elimination half-life in prairie dogs (i.v., 6.5 h and oral, 7.5 h), facilitated multiple dosing PK and safety assessment. The allometry-based predicted values of the Vss and CL were within 2.0 and 2.5-fold, respectively, of the observed values. Our results suggest that prairie dogs and monkeys may be suitable rodent and non-rodent species to perform further efficacy testing of these TKIs against orthopoxvirus infections. The use of rodent models such as C57BL/6 mice and guinea pigs for assessing pre-clinical anti-viral efficacy of these two TKIs may be limited due to short elimination and/or low oral bioavailability. Allometry-based correlations, derived from existing literature data, may provide initial estimates, which may serve as a useful guide for pre-clinical PK studies in untested animal models.

26 March 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
MPMarie A de Perio
Marie A de Perio
KHKatherine A. Hendricks
Katherine A. Hendricks
CDChad H Dowell
Chad H Dowell
WBWilliam A Bower
William A Bower
NBNancy C. Burton
Nancy C. Burton
JAJames Antonini
James Antonini
Since 1997, nine cases of severe pneumonia, caused by species within the B. cereus group and with a presentation similar to that of inhalation anthrax, were reported in seemingly immunocompetent metalworkers, with most being welders. In seven of the cases, isolates were found to harbor a plasmid similar to the B. anthracis pXO1 that encodes anthrax toxins. In this paper, we review the literature on the B. cereus group spp. pneumonia among welders and other metalworkers, which we term welder’s anthrax. We describe the epidemiology, including more information on two cases of welder’s anthrax in 2020. We also describe the health risks associated with welding, potential mechanisms of infection and pathological damage, prevention measures according to the hierarchy of controls, and clinical and public health considerations. Considering occupational risk factors and controlling exposure to welding fumes and gases among workers, according to the hierarchy of controls, should help prevent disease transmission in the workplace.